Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) had its target price raised by equities research analysts at JPMorgan Chase & Co. from $22.00 to $24.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s price target would suggest a potential upside of 18.12% from the stock’s previous close.
Several other research firms have also recently issued reports on AMRX. Weiss Ratings upgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. UBS Group reaffirmed a “buy” rating on shares of Amneal Pharmaceuticals in a research note on Thursday, October 1st. Barclays upped their price target on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, September 17th. Leerink Partners began coverage on Amneal Pharmaceuticals in a research note on Wednesday, September 9th. They set an “outperform” rating and a $23.00 price objective on the stock. Finally, Zacks Research downgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $21.25.
Check Out Our Latest Stock Analysis on Amneal Pharmaceuticals
Amneal Pharmaceuticals Price Performance
Shares of NASDAQ AMRX opened at $20.32 on Thursday. Amneal Pharmaceuticals has a twelve month low of $9.99 and a twelve month high of $21.17. The firm has a 50-day moving average of $18.68 and a two-hundred day moving average of $16.36. The company has a market capitalization of $6.49 billion, a price-to-earnings ratio of 41.60, a PEG ratio of 2.33 and a beta of 1.22. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. The company had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, analysts expect that Amneal Pharmaceuticals will post 0.95 earnings per share for the current fiscal year.
Insider Buying and Selling at Amneal Pharmaceuticals
In related news, EVP Jason B. Daly sold 210,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the sale, the executive vice president owned 35,171 shares in the company, valued at $611,975.40. This represents a 85.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the sale, the executive vice president directly owned 253,390 shares of the company’s stock, valued at approximately $4,436,858.90. This trade represents a 36.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 413,016 shares of company stock worth $7,216,567. 17.30% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Amneal Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Signature Wealth Management Partners LLC bought a new position in shares of Amneal Pharmaceuticals during the third quarter valued at about $4,681,000. Diversify Advisory Services LLC grew its position in Amneal Pharmaceuticals by 572.1% in the 3rd quarter. Diversify Advisory Services LLC now owns 119,275 shares of the company’s stock worth $2,296,000 after purchasing an additional 101,529 shares in the last quarter. Quantum Financial Partners LLC increased its stake in Amneal Pharmaceuticals by 19.4% in the 3rd quarter. Quantum Financial Partners LLC now owns 12,300 shares of the company’s stock valued at $248,000 after buying an additional 2,000 shares during the last quarter. Fortitude Family Office LLC increased its stake in Amneal Pharmaceuticals by 100.9% in the 3rd quarter. Fortitude Family Office LLC now owns 1,607 shares of the company’s stock valued at $32,000 after buying an additional 807 shares during the last quarter. Finally, GK Wealth Management LLC purchased a new stake in Amneal Pharmaceuticals in the 3rd quarter valued at about $103,000. 31.82% of the stock is owned by hedge funds and other institutional investors.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.
The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.
Recommended Stories
- Five stocks we like better than Amneal Pharmaceuticals
- There’s a New Q in Town: Invesco’s ETF Targets International Innovators
- Boarding Now—GE Aerospace’s Earnings Beat Comes With a Catch
- AI Spending Is Surging—But Which Stocks Still Win if It Slows Down?
- Are RTX Corporation and Northrop Grumman Ready to Break Out?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
